Medpace Holdings, Inc. $MEDP Stake Cut by Wasatch Advisors LP

Wasatch Advisors LP lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.7% in the 2nd quarter, Holdings Channel reports. The firm owned 636,595 shares of the company’s stock after selling 137,336 shares during the quarter. Medpace accounts for approximately 2.2% of Wasatch Advisors LP’s portfolio, making the stock its 5th largest position. Wasatch Advisors LP’s holdings in Medpace were worth $337,134,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. AQR Capital Management LLC increased its position in shares of Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after buying an additional 324,293 shares during the period. Geode Capital Management LLC boosted its position in shares of Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares during the period. Invesco Ltd. grew its stake in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after acquiring an additional 85,517 shares in the last quarter. Renaissance Technologies LLC grew its stake in Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after acquiring an additional 38,760 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Medpace by 5.5% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 395,769 shares of the company’s stock worth $190,044,000 after acquiring an additional 20,736 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 0.5%

Shares of MEDP stock opened at $605.50 on Wednesday. The business has a 50-day moving average price of $528.36 and a two-hundred day moving average price of $491.85. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The firm has a market cap of $16.90 billion, a P/E ratio of 35.49, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 31,087 shares of company stock worth $16,203,054 over the last ninety days. Insiders own 20.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Truist Financial increased their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. BMO Capital Markets boosted their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and upped their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Finally, Mizuho lifted their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Two analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.